LMB In The News

The Cambridge News highlights Melina Schuh’s work on the development of mammalian oocytes into fertilisable eggs. Errors during this process are common causes of miscarriages and genetic defects such as Down’s syndrome. This article is no longer available from the source website: Cambridge News 17 February 2015

The end of the antibiotic age? The LMB’s Venki Ramakrishnan took part in a panel discussion on the problem of antibiotic resistance at the World Economic Forum in Davos. In an interview with Katia Moskvitch, he tells us about the importance of gaining a better understanding of the use and misuse of these drugs. More…

A cover image designed by Stephen Wallace from Jason Chin’s group at the LMB and Paul Margiotta from the LMB’s visual aids department is included in the Royal Society of Chemistry blog on cover art and the people who make it. This article is no longer available from the source website: Royal Society of Chemistry.

A new study, involving LMB researchers and former LMB group leader, Sarah Teichmann, describes a fundamental mechanism regulating a protein’s shape and function, with potential applications in biotechnology and drug development. More…

LMB group leader Sjors Scheres is profiled by Nature as one of its ten people of the year, for his work on bringing the cell’s molecular machines into sharper focus, with the use of cryo-EM. More…

Heptares Therapeutics, a leading G protein-coupled receptor (GPCR) structure-guided drug discovery company, has recently been granted multiple key patents in the USA. GPCRs are a superfamily of drug receptors linked to a wide range of human diseases and Heptares was founded in 2007 to develop and commercialise pioneering research from the LMB and the National Institute of Medical Research (NIMR) to find new medicines targeting GPCRs. Sir John Saville presented the inventors with a memento to mark the award of these key patents for the GPCR-focused drug discovery platform. More…